we'd and to thanks very also the any some everyone, be joining to morning, for and Then fourth our take recent Good Rob. XXXX results updates. pleased exciting questions. to of Thanks, for us review quarter financial hear
XXXX, ibezapolstat candidate including Phase November data antibiotic clinical of fourth reported trial October our difficile 'XX, key I'll in end cases, in oral or II C. ended infection XXXX, Phase or lead Phase trial of in patients our overall results in X, of included standard IIb First, line quarter our from care, CDI. at vancomycin treatment compared X, IIa; which XX%, enrollment XX demonstrating with was for the shortly for the Phase XX full of On of clinical treatment XX% or thereafter. the IIb cures. days with study, IIb ibez, we some activities at or for some of end which the arm, On patients, cure the cure clinical or with we ibezapolstat, top summarize rate cure XX XXX% XX control XX% and and from Phase at treatment or XX EOT sustained of of XXX%
of both safety recorded concerns clinical Phase either in IIb were vancomycin-controlled all tolerated and in was the patients arm No trial, and trial in the Phase open-label the ibezapolstat segment. IIa Phase IIb well
data, trial established. of high observed cure blinded In concerns. on safety consultation determined advisers, the was no that based segment emerging the with review early company clinical terminated to rates Clinical Phase due aggregate IIb was vancomycin-controlled comparability scientific our success showing with
trial be as after after XX impact microbiome. on segment, also clinical -- available extended the as data data becomes We IIb the at and XX well clinical an provided data EOT comparative EOT on exploratory would as for including further at that stated patient's that the further days data secondary and cure days Phase endpoints it sustained cure on
patients that days reinfection who while showed of XX.X%, cured XX patients advanced sustained XX were XX of XXX% trial announced X with the 'XX, December of XX, clinical rate cured in at segment, data. IIb the experienced we or a reinfection later Phase vancomycin no cure EOT of On These were reinfected. data XX remain our
difficile in vancomycin, data vancomycin, C. eradication XX comparative at showing microbiology day segment. difficile the from Phase fecal of patients trial had XXXX, announced for On we ibezapolstat outperformed IIb in versus C. of patients XX clinical CDI of treated just positive XX January X XX and Ibezapolstat of patients. which XX, microbiome eradication treatment in of treated
Additional but confer consistently vancomycin data of and species health IIb regrowth bacterial believed allowed prevention to trial recurrent from not difficile key clinical preserved showed benefits Phase of ibezapolstat, the including infection. C.
trial provide anticipate the III that ultimately, and data in endpoints exploratory the We secondary from these in options our favorable X approved. if marketplace, Phase will between separation further therapeutic and clinical program,
and Additional exploratory forthcoming other become data endpoints secondary will regarding analyses be as available.
ibezapolstat antibiotic about for appropriately the acute treat excited difficile of believe particularly dual is which We long-term we C. managing infection remain patient's therapy. of microbiome, to while the care exceptional impact each
FDA would scheduled and meeting on our to occur April. this discussing minutes anticipate trial documented Feb in anticipate information clinical mandate end XX We we a an of by is to and robust to clinical Phase granted February in III from early preclinical, was FDA manufacturing Phase package date, sometime FDA data year. which at this meeting, request II and for formidable Having in with submitted a along meeting
We our to European also announced application support small- benefits, in which from for authorization Agency Medicines for be seeking enterprise SME, designated provides a Europe. Medicines as including that approved to Europe, certain reductions fee the European a or other Agency marketing in medium-sized and
up for registration Partners put the Alliance planned Commission ATM used or In Exchange mandate. Phase statement $XX XXXX, purposes sales we an be and trial clinical the Global III ATM Proceeds going agent aftermarket general to November a Securities forward filed corporate with our as amendment a will from million the to with company. shelf acting including facility our and
Dr. spectrum in aspects Antimicrobials the "New University of trial and the preclinical DeLuccia, Also trial. a pol our behalf Pipeline."
Now inhibitors our microbiome of IIIC of Week, of class In Professor that's from of Dr. of new data novel digest. you October pipeline clinical Bob Many Pharmacy may to for presented symposium Chair, Chairman, investigator and in Phase Garey Week, the program. College Houston our at Executive our ibezapolstat with lot the clinical presented on recall is IIa ID ID of XXXX DNA at at our entitled, principal activity our activity Kevin selective Garey
today. to I'll we So summarize as further are where
Phase we're upcoming advance to also the a III trials meeting ibezapolstat favorable agreement application Phase for into anticipate a preparing U.S. speak, the from III approval to regulatory and and pathway FDA proceed we drug obtain new completed. As to filing once is regarding on our in readiness outcome marketing clinical for
a III regulatory for to started marketing and to allow include list other officially and overall also and the international will approval. The We've money international to U.S. us of commercial sites This and time will trials add enrollment us ultimate Europe to the filings process this will regulatory in our later Phase support year. enhance territories lot expand reach. and save
clinical enrollment conduct our To ensure getting our our time arms trial around clinical we're Phase trial we plan is our to company III sites, III quickly required way number to adding to the above trials efficiently. size and U.S.-only but Phase We're the conduct substantially need as more concurrently, used possible, II lines, Phase costs financial now our as resources registration most use and not the consecutively, the X of trials. given
in a concern with in trial of Europe, our years for regulatory date since approval the the legislation U.K. line exclusivity U.S. XX will not a Japan. is rolling the III from conduct similar time and ibezapolstat have of FDA Phase The
well and alongside company, potential clinical transaction for We U.S. III a arrangement strategic licensing potential including merger, partner trials. parallel in other a ibezapolstat development our as potential of will the with or third-party the transaction Phase further territorial continue commercialization as to seek for strategic for ex sale, preparation and
this commitments initiative from February have with we time, others IIb provide was potential no our released. recently this only to in company the At we partners but after started Phase or data capital,
excited M&A steps forward, Phase the enrollment and we plans formidable X partnering, as over A So equally we're XX about ] next basically, have next going months. III [ and
such designation a treatment, As we've low Track continues CDC Fast for threat that outperform infectious of U.S. in to also treatment of potentially consistently of initial for disease as C. recurrence. FDA but the also need ibezapolstat has has categorizes urgent of series difficile Ibezapolstat antibiotics for C. and there's difficile incidence new classes in called reported, infection. a an a life-threatening
impact our the difficile current Additionally, believe estimated We make system, which annually. is by if the could burden we to yet on care billion best a C. is do believe favorable health of $X.X reducing ibezapolstat, U.S. infection at approved, cost come.
Shawah, you the And guide results our through and Rob CFO, quarter to year of our financial now for XXXX. Rob? full back to highlights the fourth
